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The degradation of cytochromes P-450 by fluroxene 
(2,2,2-trifluoroethyl vinyl ether) has been investigated. 
Fluroxene is shown to specifically degrade cytochromes 
P-450 in vivo and in vitro without affecting the levels 
of the other microsomal enzymes, cytochrome ~S a.nd NADPH-
cytochrome~ reductase. Fluroxene appears to degrade 
the haem moiety of cytochromes P-450 but does not affect 
the level of the apoprotein. The degradation of cyto-
chromes P-450 by fluroxene is accompanied by a loss of 
E-nitroanisole 0-demethylase and biphenyl 4-hydroxylase 
activities and a decrease in the extent of aniline binding 
is observed. 
By using cytochromes P-450 dependent reactions which 
are catalysed by specific type P-450 cytochromes,~.~· the 
hydroxylation of benzpyrene, the N-demethylation of ethyl-
morphine and the binding of ethyl isocyanide, it is 
established that only cytochrome P-450 is degraded by 
fluroxene in vivo following phenobarbital induction of 
animals, and both cytochrome P-450 and cytochrome P-448 
following methylcholanthrene induction. The same type 
P-450 cytochromes are shown to be degraded by fluroxene 
in vitro in phenobarbital and methylcholanthrene induced 
microsomes. This was established from studies of the 
kinetics of the fluroxene mediated degradation of cyto-
chromes P-450. In addition, the K values for the flurox-m 
ene mediated degradation of cytochromes P-450 differ with 
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the different inducing agents and indicate the involve-
ment of two different type P-450 cytochromes in the 
degradation reaction in methylcholanthrene induced micro-
somes. 
Metabolic activation of cytochromes P-450 by the cyto-
chromes P-450 drug metabolising pathway appears to be 
essential for the fluroxene mediated degradation of cyto-
chromes P-450. Since none of the known or proposed 
metabolites of fluroxene can mimic the degradation of 
cytochromes P-450 by fluroxene, a reactive species is 
proposed to be involved. By varying the experimental 
conditions, and with the use of inhibitors of cytochromes 
P-450, the likely sequence of events in the fluroxene 
mediated degradation of cytochromes P-450 is shown to be 
as follows: fluroxene is metabolised by cytochrome P-450 
to a transient reactive intermediate which has the ability 
to degrade the haem moiety of cytochrome P-450 and cyto-
chrome P-448. 
By comparing the ability of various analogues of 
fluroxene to degrade cytochromes P-450, it is established 
that the formation of the proposed reactive intermediate 
is dependent on the presence of the vinyl moiety of the 
molecule. Initial studies indicate that the reactive 
species may take the form of an epoxide. 
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I INTRODUCTION 
Fluroxene (2,2,2-trifluoroethyl vinyl ether) is a 
volatile anaesthetic agent that was introduced into clinical 
practice in 1953 (1) and was the first volatile fluorinated 
compound utilized to anaesthetise man. Although fluroxene 
accumulated a considerable record of clinical safety (2,3), 
it has recently been shown to be toxic to many animal 
species (4-7) and, under certain conditions, to man (8-11). 
As a result of these toxicity studies, fluroxene was with-
drawn from the market by the manufacturers in 1977, but is 
still in limited use as an anaesthetic agent. 
Fluroxene has been shown to undergo metabolism in 
animals and man in vivo (12-15). The structures of 




FIGURE 1 Structures of fluroxene and possible metabolites 
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The only known metabolite of the vinyl portion of the 
molecule is carbon dioxide, but this compound only accounts 
for 10% of the fluroxene metabolised {12). In animal 
species the main metabolite arising from the trifluoro-
ethyl portion of fluroxene is trifluoroethanol, which 
appears in the urine as the glucuronide, whereas only traces 
of trifluoroacetic acid are produced {12). In contrast, 
trifluoroacetic acid has been found to be the main metab-
olite of the trifluoroethyl portion of fluroxene in man, 
with trifluoroethanol-glucuronide appearing as a minor 
metabolite (13). Trifluoroacetaldehyde has been implicated, 
but never identified, as an intermediate in the formation 
of trifluoroacetic acid from fluroxene (7,14). Metabolites 
of fluroxene, and not the anaesthetic agent itself, are 
thought to result in the toxic effects of fluroxene adminis-
tration. Trifluoroethanol, the major metabolite of 
fluroxene in many animal species, is itself toxic to labora-
tory animals (7,16). 
The endoplasmic reticulum has been shown to be the site 
of the metabolism of fluroxene and other organic compounds 
in vivo (12). This subcellular structure cannot be 
isolated from the cell intact. On homogenization of the 
cell, the endoplasmic reticulum is disrupted and segments 
of the membrane seal to form tiny vesicles, known as 
microsomes (17). Microsomes form a convenient system for 
in vitro studies of drug metabolism by the enzymes of the 
endoplasmic reticulum. 
Microsomal enzymes are responsible for the detoxification 
3 
of potentially harmful substances such as drugs, environ-
mental pollutants and carcinogens. In general, the 
microsomal drug metabolising system renders lipophilic 
compounds more hydrophilic so that they can be readily 
excreted by the kidneys. This process diminishes the 
harmful effects of the accumulation of hydrophobic sub-
stances in the body. Although the metabolism of compounds 
by hepatic microsomal drug metabolising enzymes is generally 
a detoxification process, there are cases where the bio-
transformation of a compound by this pathway results in 
the formation of metabolite(s) of increased toxicity or 
carcinogenicity relative to the parent compound. For 
example, the toxicity of vinyl chloride appears to result 
from the conversion of this compound to reactive species 
such as chloroethylene oxide or chloroacetaldehyde by the 
microsomal mixed function oxidases (18). In addition, 
the metabolism of benzpyrene gives rise to a number of 
hydroxylated products, one or more of which are carcino-
genic, whereas the parent compound is not {19,20). 
The metabolism of drugs and xenobiotics is considered 
to occur in two phases: the first phase involves the 
oxidation of lipophilic compounds, and the second phase 
involves conjugation of the oxidized compound with a small 
polar molecule. The first phase of the microsomal electron 
transfer pathway is catalysed predominantly by the cyto-
* chromes P-450 dependent drug metabolising pathway. The 
* In this thesis, the terms "cytochromes" P-450, "type P-450 
cytochrornes'' and "cytochrome P-450 haemoproteins" refer to 
the heterogeneous mixture. The terms "cytochrome P-450" 
and "cytochrome P-448" refer to the specific enzymes. 
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second phase gives rise to a relatively hydrophilic com-
pound for excretion by the kidneys (21,22}. The compon-
ents of the microsomal drug metabolising pathway are 
found in highest concentrations in the liver, with the 
next highest amount in the kidneys. Low, but measurable, 
levels are found in most organs and tissues (23). 
The cytochrornes P-450 drug metabolising pathway consists 
of a group of enzymes of broad substrate specificity. 
These enzymes are responsible for the metabolism of a wide 
variety of xenobiotics, such as drugs, insecticides, 
herbicides, food preservatives and carcinogens. The basic 
reaction catalysed by the cytochromes P-450 drug metabolism 
pathway is as follows: 
where SH and SOH represent substrate and hydroxylated 
product respectively. The types of oxidative reactions 
catalysed by the cytochromes P-450 include deamination, 
0- and N-dealkylation, N-oxidation, sulfoxidation, and 
hydroxylation of aryl and alkyl amines. 
( 1) 
Cytochrornes P-450 are a heterogeneous group of enzymes 
of diverse substrate specificities. These enzymes were 
named for their most striking spectral feature, i.~. the 
strong absorbance at 450 nm of the carbon monoxide-ferro-
cytochromes P-450 complex. 
cytochromes P-450 group of 
Within the heterogeneous 
enzymes, there are two spectrally 
distinct forms which have been well characterized. For 
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the one form, the absorbance maximum of the carbon monoxide-
ferrocytochrornes P-450 is at 450 nm, while for the other, 
the absorbance maximum is at 448 nm. At first, these 
were thought to represent different conformational forms 
of a single enzyme. However, recently, several different 
type P-450 cytochromes have been separated and purified 
and these different absorbance maxima are therefore attri-
butable to distinct enyzmes. Cytochrome P-450 and cyto-
chrome P-448 vary in physical properties, such as molecular 
weight, substrate specificity, antibody specificity and 
spectral properties (24-29). It is not known how many 
different type P-450 cytochromes exist, but six distinct 
cytochromes P-450 have been identified in rat liver on the 
basis of immunochemical evidence (30). Cytochromes P-450 
are known as the terminal oxidases in the microsomal mixed 
function oxidase system. 
The microsomal electron transport pathway for the 
metabolism of drugs by cytochromes P-450 is as follows: 
NADPH 
.!-




cytochrome £s SH SOH 
The arrows indicate the direction of flow of the electrons. 
Cytochromes P-450 bind substrate and oxygen and catalyse 
the reaction shown in equation 1. NADPH-cytochrome c 
6 
* reductase fulfils a role as electron carrier (31,32). 
Recent studies on the reconstitution of purified and 
solubilized components of the cytochromes P-450 drug 
metabolising pathway indicate that, in addition to cyto-
chromes P-450 and NADPH-cytochrome c reductase, a phospho-
lipid fraction is essential for drug metabolism in vitro 
( 33-35) . The active component of the phospholipid fraction, 
phosphatidylcholine, has been shown to be essential for the 
transfer of electrons from NADPH to cytochromes P-450, 
although its mode of action is unknown (36). 
It is uncertain as to whether cytochrome ~ 5 , the only 
other microsomal haem protein, plays a role in the cyto-
chromes P-450 drug metabolising pathway. Cytochrome ~S 
is not essential for drug metabolism although it is 
capable of transferring electrons to cytochromes P-450 (32). 
It seems likely that cytochrome ~ 5 plays a role in the 
synergistic effects observed when both NADH and NADPH are 
used to support hepatic microsomal drug metabolism (37). 
The levels of the cytochrome P-450 haemoproteins have 
been shown to be increased by a large variety of compounds, 
including environmental agents and drugs (38). These 
compounds are known as enzyme inducers. The inducing 
agents for cytochromes P-450 fall into two categories. 
Phenobarbital is a typical inducer of the first category 
* NADPH cytochrome c reductase can reduce artificial electron 
acceptors such as-ferricyanide and cytochrome c. This 
enzyme is commonly named NADPH-cytochrome c reductase 
because its activity is usually measured by the reduction 
of cytochrome c. It is 2,lso known as NADPH-cytochrome 
P-450 reductase (33). 
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(32,38). Phenobarbital causes proliferation of the endo-
plasmic reticulum and elevation of NADPH-cytochrome £ 
reductase, cytochrome ~ 5 and cytochrome P-450 (38,39) and 
consequently stimulates the metabolism of a large variety 
of substrates (32). The second category of inducing agents 
is typified by the polycyclic hydrocarbons, benzpyrene and 
methylcholanthrene. The polycyclic hydrocarbons elevate 
the levels of cytochromes P-450 without affecting the levels 
of the other microsomal enzymes or causing proliferation 
of the endoplasmic reticulum. The type P-450 cytochrome 
preferentially induced by the polycyclic hydrocarbons is 
known as cytochrome P-448. Induction of cytochrome P-448 
by the polycyclic hydrocarbons results in a stimulation 
of the metabolism of only a limited number of substrates, 
predominantly the hydroxylation of polycyclic aromatic 
hydrocarbons. For this reason, cytochrome P-448 is also 
known as aryl hydrocarbon hydroxylase. 
A wide variety of organic compounds bind to cytochromes 
P-450. There are several different binding sites on the 
cytochromes P-450 1 some of which are spectrally observable. 
The binding of compounds to these latter sites alters the 
environment of the haem moiety of cytochromes P-450 and 
gives rise to absorbance changes in the visible region of 
the spectrum. These structural changes have been most 
extensively characterised in terms of the formation of 
difference spectra by organic compounds in the presence 
of microsomes. More recently, these structural changes 
have been characterised in terms of the spectral changes 
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observed wj_th purified solubilized cytochroraes P-450 
(24,25,29). 
There are three cowmonly observed types of difference 
spectra, known as type I, II and IR. The type I difference 
spectrum is characterised by a peak at about 385 run and a 
trough near 420 nm (40-42) and arises from a change in the 
envirorunent of the haem moiety. The spin state of the 
haem iron ion is changed from a relatively low spin form 
to a relatively high spin form (43). Most compounds 
producing type I difference spectra undergo cytochromes 
P-450 dependent metabolism. Consequently, a type I change 
is often associated with the formation of an enzyme-substrate 
complex. A wide variety of compounds give rise to type I 
difference spectra including insecticides, herbicides, 
carcinogens and many drugs, of which the barbiturates are 
examples. 
The type II spectral change results from the liganding 
of a compound to the haem iron ion of ferricytochromes P-450. 
The type II difference spectrum is characterised by a peak 
near 430 nm and a trough at about 390 nm (40-42). Type II 
compounds are good ligands, such as primary and secondary 
amines, sulfides, carbenes and alkoxides. Aniline is the 
most common example of the type II compounds and is one of 
the few type II compounds which are substrates for cyto-
chromes P-450 (40,44). Type II compounds compete with 
carbon monoxide and oxygen as ligands for the ferrous ion 
of reduced cytochromes P-450. 
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In addition to compounds which bind to the type I and 
type II binding sites, there are compounds which give rise 
to a type IR difference spectrum (42,45). This type of 
difference spectrum is the reverse of a type I difference 
spectrum. The type IR difference spectrum is characterised 
by a peak at about 420 nm and a trough at about 385 run. 
The type IR difference spectrum arises from a change in the 
spin state of the haem iron towards a relatively low spin 
form (43). Type IR compounds are not usually substrates 
for cytochromes P-450. Examples of type IR compounds are 
alcohols and acids. Both type I and type IR compounds 
are unable to displace carbon monoxide from ferrocytochromes 
P-450. 
The binding of the substrate to ferricytochromes P-450 
is the first step in the cytochromes P-450 dependent 
metabolic pathway. The detailed mechanism for cytochromes 
P-450 catalysed reactions is shown diagramatically in 
figure 2. As shown in the scheme, the ferric form of 
cytochromes P-450 first binds the substrate (SH) and then 
accepts one electron from NADPH to form the ferrous cyto-
chromes P-450-substrate complex. This complex then com-
bines with molecular oxygen and accepts a second electron 
from NADPH. At this stage events become uncertain, but 
it has been proposed that a ferrous enzyme-superoxide 
intermediate is formed which is in resonance with the 
ferric-hydroperoxo complex (46). This complex is unstable 
yielding a ferric enzyme-monooxygen species which is in 












































































































































































































































































species decomposes giving rise to the hydroxylated product 
(SOH) and regenerating the ferric form of the enzyme. 
The hydroxylated product usually undergoes further 
reaction via other enzymes such as conjugation with a 
small physiological polar molecule. Conjugation with 
glucuronic acid (glucuronidation) or sulphate (sulphation) 
are common examples of such reactions (47). The conjugated 
product is usually devoid of biological activity and is 
readily excreted in the urine or bile. 
The interaction of fluroxene with the cytochromes P-450 
dependent drug metabolising pathway has been studied in 
detail in our laboratories (48). Fluroxene has been shown 
to bind to the type I binding site of cytochromes P-450 in 
vitro. The K values for the binding of fluroxene to cyto-s 
chromes P-450 (approximately 0,9 mM) are identical for 
differently induced microsomes. The metabolism of fluroxene 
by the cytochromes P-450 dependent pathway has been investi-
gated by measuring the rates of NADPH consumption (48) and 
of 2,2,2-trifluoroethanol production (96). A stoichio-
metric relationship between the rates of trifluoroethanol 
production and the rates of NADPH oxidation was observed 
for the metabolism of fluroxene indicating that the metab-
olism of fluroxene follows the equation for a typical 
cytochromes P-450 reaction (equation 1). The K values 
m 
for the metabolism of fluroxene as measured by NADPH 
consumption were found to be approximately 0,8 mM and did 
not vary with differently induced microsomes. The close 
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agreement between the K and K values for the binding s m 
and metabolism of fluroxene suggests that the spectrally 
observable binding constant (K} for fluroxene reflects s 
the formation of the substrate-cytochromes P-450 complex. 
Since the K and K values are similar, the rate limiting s m 
step for the metabolism of fluroxene is probably subsequent 
to the binding of fluroxene to ferricytochromes P-450. 
In contrast to the similarity between the K and K s m 
values for the metabolism of fluroxene by differently 
induced microsomes, the ~A and V values differ with max max 
different inducing agents. The ~A value is approxi-max 
rnately two-fold greater in phenobarbital induced microsomes 
than in uninduced, benzpyrene and methylcholanthrene induced 
microsomes. Similarly, Vmax is shown to be elevated 
approximately three-fold by phenobarbital induction compared 
to control or other inductions. From the binding and 
metabolism data, it was concluded that cytochrome P-450, 
the type P-450 cytochrome induced by phenobarbital, is 
primarily responsible for the binding and metabolism of 
fluroxene, although cytochrome P-448 may be involved to a 
small extent. 
One unexpected aspect of the interaction of fluroxene 
with the cytochromes P-450 drug metabolising pathway, was 
the ability of fluroxene to degrade cytochromes P-450 in 
vivo and in vitro. This phenomenon has been demonstrated 
for a number of compounds, including the allyl containing 
barbiturates, AIA, and carbon tetrachloride (49-54). 
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AIA has been shown to degrade the haem moiety of cytochromes 
P-450 in vivo and in vitro without affecting the levels of 
other microsomal enzymes. In addition to the ability of 
AIA to destroy cytochromes P-450, AIA stimulates the 
activity of 5-aminolevulate synthetase, which causes an 
over production of porphyrins, leading to experimental 
porphyria (55-58). In contrast, carbon tetrachloride is 
non-specific in its degradation of cytochromes P-450 and 
results in the loss of other microsomal proteins, and the 
mechanism of degradation of cytochromes P-450 by carbon 
tetrachloride appears to differ from that of AIA. Lipid 
peroxidation has been proposed to be involved in the 
degradation of microsomal enzymes by carbon tetrachloride 
(50, 59-61). 
This thesis investigates the degradation of hepatic 
cytochromes P-450 by fluroxene, especially with respect to 
the following: 
1. Which of the type P-450 cytochromes are degraded by 
fluroxene. 
2. The stage during the metabolism of fluroxene at which 
the destruction of hepatic cytochromes P-450 occurs. 
3. The role played by different cytochromes P-450 in the 
fluroxene mediated destruction of hepatic cytochromes 
P-450. 
4. The portion of the fluroxene molecule that is respon-
sible for the destruction of cytochromes P-450. 
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II MATERIALS 
Sodium phenobarbital and methylcholanthrene were 
obtained from Maybaker, S.A. and Eastman Kodak, respec-
tively. Fluroxene (2,2,2-trifluoroethyl vinyl ether) 
was supplied by Ohio Medical Products, Madison, Wisconsin. 
Ethyl vinyl ether and divinyl ether were ob ained from 
Fluka, Buchs, Switzerland and Maybaker, S.A. respectively. 
Trifluoroethyl ethyl ether was prepared by hydrogenation 
of fluroxene as previously described (62). Trifluoro-
acetaldehyde was purchased from ICN Pharmaceuticals, 
Plainview, New York, and trifluoroethanol and trifluoro-
acetic acid were from Merck. NADP, NADH and glucose-6-
phosphate dehydrogenase were obtained from Miles Labora-
tories, Cape Town. NADPH, cytochrome C (Type III), 
benzpyrene and reduced glutathione were obtained from 
Sigma Chemicals. £-Nitroanisole was obtained from 
Eastman Kodak and was recrystallised from petroleum ether 
0 0 (b.p. 100 - 120 ) . Glucose-6-phosphate was obtained 
from Koch-Light Laboratories. Biphenyl and 4-hydroxy-
biphenyl were purchased from Merck-Schuchard and recrys-
o 0 tallised from ethanol and petroleum ether (b.p. 100 - 120 ) 
respectively. 2-Hydroxybiphenyl was obtained from BDH 
Chemicals Limited and was recrystallised from petroleum 
0 0 ether (b.p. 100 - 120 ) . Succinic acid was obtained 
from Merck and recrystallised from distilled water. 
Cylinders of pure gases were obtained from Afrox Limited. 
Metyrapone [2-methyl-l,2-bis(3-pyridyl)-l-propane] and 
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SKF 525-A (S-diethylaminoethyl-2,2-diphenyl valerate) were 
generous gifts from Ciba-Geigy Limited, Basle, Switzerland, 
and Smith, Kline and French, Ltd. respectively. AIA 
(2-allyl-2-iso-propylacetamide) was a generous gift of 
Hoffman-La Roche, Nutley, New Jersey. Mr. G.H. Blekken-
horst (Department of Medicine, University of Cape Town) 
generously supplied the ethyl isocyanide. All other 




1. Induction of animals 
Male Wistar rats weighing between 180 g and 250 g were 
used in all experiments. The animals were allowed free 
access to Epol Laboratory Chow (protein min. 20%, fat 2,5%, 
fibre max. 6%, calcium 1,4%, phosphorus 0,7%) and water 
unless otherwise indicated. Cytochromes P-450 were induced 
by intraperitoneal injections of sodium phenobarbital 
(80 mg/kg/day) or methylcholanthrene (40 mg/kg/day) for 3 
consecutive days. All animals were starved overnight 
after the last injection and sacrificed by cervical fracture 
the following morning. 
2. Preparation of microsomes 
Microsomes were prepared at 4° from fresh rat liver 
homogenates by gel filtration on Sepharose 2B equilibrated 
in 0,15 M KCl - 0,02 M Tris-HCl pH 7,4 according to the 
method of Tangen et al. (63). Microsomes were also 
prepared by differential ultracentrifugation according to 
the method of Holtzman and Carr (64) with the following 
modifications: the liver was homogenized in 3 ml 0,15 M 
KCl - 0,02 M Tris-HCl pH 7,4, for each gram wet liver 
weight. The debris and mitochondria were removed by 
centrifugation at 10 000 g for 15 min in a Beckman J-21B 
centrifuge. The microsomes were sedimented from the 
supernatant by centrifugation at 105 000 g for 1 hr in a 
Beckman model L ultracentrifuge. The microsomal pellet 
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washed with 0,15 M KCl - 0,02 M Tris-HCl and resedimented 
by centrifugation at 105 000 g for 45 min. The microsomes 
were finally suspended in 0,02 M Tris-HCl pH 7,4. This 
preparation of microsomes was used following in vivo 
destruction of cytochromes P-450 by fluroxene. Immedi-
ately after isolation of the microsomes, the protein 
concentration of the microsomal suspension was determined 
by the method of Lowry et al. (65} as modified by Chaykin 
(66}, using bovine serum albumin as a standard. The 
microsomes were diluted to a concentration of 2 mg micro-
somal protein/ml with 0,02 M Tris-HCl and used at this 
concentration in this buffer in subsequent experiments 
unless otherwise stated. 
3. Preparation of electron transport particles 
Mitochondria were prepared from fresh beef heart by differ-
ential ultracentrifugation (67} using 0,9% KCl in the final 
wash. Electron transport particles were prepared from the 
mitochondria by the method II of Crane et al. (68} and 
were finally suspended in 0,25 M sucrose. The activity 
of the electron transport particles under the conditions 
of the anaerobic experiments was determined in the presence 
of succinate using a Clark type oxygen electrode. The 
recorder was calibrated with air saturated solutions 
(278 µM oxygen} and zeroed on solutions containing an 
excess of the oxygen scavenger sodium dithionite (0 µM oxygen}. 
By comparison, the activity of the electron transport 
particles was found to be 0,05 - 0,20 µmol oxygen consumed/min. 
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4. Destruction of cytochromes P-450 in vitro 
Destruction studies were carried out in the presence of a 
NADPH generating system containing 0,4 mM NADP, 7,4 mM 
glucose-6-phosphate, 0,5 U/ml glucose-6-phosphate dehydrog-
enase, 5 mM MgC1 2 , 1 ITLM nicotinamide and 0,2 mM EDTA (final 
concentrations). 3,0 ml of microscmal suspension was 
pipetted into vials of appropriate size so that the air 
space in the vial was approximately 10 - 15% of the total 
volume once the vial was stoppered with a serum cap. 
Samples and reaction blanks, the latter comprised only of 
microsomal suspension, were preincubated at 30° for 2 min. 
The NADPH generating system - EDTA mixture and then the 
compound to be tested were introduced below the surface 
of the microsomes in the sample. The vial was sealed 
immediately with a serum cap and the reaction was initiated 
by mixing. In the case of lipophilic reagents, vortex 
mixing was performed for 30 sec to initiate the reaction. 
Samples and blanks were incubated with shaking in a 
0 
Galenkarnpstat shaking water bath at 30 . At the end of 
the incubation period, samples and blanks were removed 
and assayed immediately for the levels of the different 
microsomal enzymes. 
5. Determination of the rate constants for the destruction 
of cytochromes P-450 by fluroxene in vitro 
Determination of the rate constants for the destruction of 
cytochromes P-450 was performed as described earlier, except 
that a booster consisting of 0,4 mM NADP, 7,4 mM glucose-6-
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phosphate, and 0,5 U/ml glucose-6-phosphate dehydrogenase 
(final concentrations) was added at every eighth min 
during the course of the reaction. Cytochromes P-450 
values were corrected for the dilution caused by addition 
of the booster and also for the small, but significant, 
loss of cytochromes P-450 observed only in the presence of 
NADPH generating system plus phenobarbital induced micro-
somes. 
6. Experiments under total anaerobic conditions 
A mixture of microsomal suspension (2 mg protein/ml, final 
concentration) and electron transport particles (0,4 mg 
protein/ml, final concentration) in 0,02 M Tris-HCl, pH 
7,4, was deoxygenated for 15 min by repeated flushing with 
deoxygenated nitrogen and evacuation by aspiration. This 
treatment resulted in a decrease in the oxygen content to 
approximately 15% that of air saturated microsomes, as 
measured by a Clark type oxygen electrode. All subsequent 
procedures were carried out in a nitrogen bag which was 
continually flushed with argon or oxygen free nitrogen. 
All solutions added to the microsomes in subsequent steps 
had been previ0usly deoxygenated by bubbling with oxygen 
free nitrogen for 15 min. To further decrease the oxygen 
content of the incubdtion mixture, succinate (10 mM, final 
concentration) was added to the suspension mixture and 
3,0 ml aliquots were pipetted into 4 ml cuvettes with gas 
tight teflon stoppers. NADPH generating system and 
fluroxene were then added to the microsomes as previously 
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described, and the solution was vortex mixed. The 
cuvettes were removed from the nitrogen bag and incubated 
at room temperature without shaking. Assay by oxygen 
electrode of these samples indicated that the levels of 
oxygen were effectively zero and could not be decreased 
following addition of the oxygen scavenger sodium dithio-
nite. In addition, the 0-demethylation of E-nitroanisole, 
which proceeds aerobically with a first order rate constant 
-1 
of 0,2 min , did not proceed measurably over 10 min under 
the anaerobic experimental conditions. 
7. Destruction of cytochromes P-450 in vivo 
Two groups of 3 to 4 rats each of almost identical weights 
(190 ~ 5 g) were induced with sodium phenobarbital or 
methylchclanthrene as described. The rats were starved 
overnight after the last injection and one group received 
fluroxene by intraperitoneal injection or AIA by sub-
cutaneous injection the next morning. In the case of 
phenobarbital induction, the rats received 2 ml/kg 
fluroxene or 200 mg/kg AIA and were killed 55 + 5 min 
thereafter. In the case of methylcholanthrene induction, 
the rats received 5 ml/kg fluroxene and were killed 85 + 5 
min after fluroxene treatment. 
8. Spectrophotometry 
Unless otherwise stated, all spectral measurements were 
performed using a Unicarn SP 1800 recording spectrophoto-
meter with a Unicarn AR 25 recorder. The thermostatted 
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cell position adjacent to the photomultiplier was used 
throughout and cuvettes were placed so that the frosted 
cell surface was in the light path. 
9. Difference spectra 
9.a Determination of binding constants 
The binding constants (K) of analogues and metabolites s 
of fluroxene were determined spectrally. 3,0 ml of micro-
somal suspension in 4 ml cuvettes were equilibrated to 30°. 
The compound under investigation was added to the sample 
cuvette below the surface of the microsomal suspension. 
The cuvette was then stoppered and, in the case of lipo-
philic compounds, vortex mixed. The magnitude of the 
resultant difference spectrum was measured as the difference 
in absorbance between the peak centred near 385 nm and the 
trough at approximately 420 Tu~. The spectrum was corrected 
for baseline irregularities recorded before the addition 
of the compound. K and 6A values were calculated from s max 
computer generated Hanes plots of [s] versus 6A/[s] and 
were checked for linearity using the more sensitive Eadie 
Hofstee plots of 6A versus 6A/[s]. 
9.b Ethyl isocyanide binding 
The crossover pH of ethyl isocyanide binding was 
determined by a modification of the methods of Imai and 
Sato (69) and Sladek and Mannering (70) as follows: 
3 volumes of microsomal suspension (2 mg protein/ml) were 
added to 1 volume of 0,4 M potassium phosphate buffer of 
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various pH. The microsomal suspension was divided equally 
between 2 cuvettes and 0,6 µl (final concentration, 2,8 mM) 
of ethyl isocyanide was added to the sample cuvette and 
the suspension was then vortex mixed for 10 sec. The 
contents of both cuvettes were reduced with sodium 
dithionite and the resulting difference spectrum and pH 
were recorded at room temperature. The magnitudes of the 
absorbance peaks at 430 nm and 454 nm were measured rela-
tive to 500 nm. 
9.c Aniline binding 
The binding of aniline to cytochromes P-450 was 
measured at 87 mM aniline (final concentration). The 
resultant type II difference spectrlun was measured as the 
difference in absorbance between 430 nm and 385 nm. This 
concentration of aniline was shown to give a difference 
spectrum equivalent to ~A max 
10. NADPH oxidation 
The metabolism of analogues and metabolites of fluroxene 
were measured by monitoring the rate of NADPH consumption 
in the presence of these compounds. 3,0 ml of microsomal 
suspension in 4 ml cuvettes was equilibrated to 30°. 
Varying amounts of the compound under investigation were 
added as described for the difference spectra. Sample 
cuvettes were vortex mixed and the reaction was initiated 
with the addition of 50 µl (0,12 m,_1\1, final concentration) 
of NADPH. The decrease in absorbance at 340 nm due to 
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NADPH oxidation was recorded spectrally against a reaction 
blank containing only microsomes. All values were corrected 
for any non-cytochromes P-450 dependent NADPH oxidation 
according to the method of Stripp et al. (71). 
V values were calculated as were the K and ~A values. max s max 
11. Enzyme assays 
11.a Cytochromes P-450 
The concentration of cytochromes P-450 was determined 
by measuring the difference spectrum between carbon monox-
ide plus sodium dithionite reduced microsomes versus sodium 
dithionite reduced microsomes as described by Omura and 
Sato (72). 
11.b Cytochrome £s 
The concentration of cytochrome b 5 was determined by 
the difference spectrum between NADH reduced microsomes 
and microsomes as described by Omura and Sato (72). 
11.c NADPH-cytochrome c reductase 
The activity of NADPH-cytochrome c reductase was 
determined spectrally by the rate of reduction of cytochrome 
c as described by Omura and Takesue (73). 
11.d Microsomal haem 
The concentration of microsomal haem was determined 
as the reduced pyridine haemochromogen as described by 
Omura and Sato (72). 
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11.e Glucose-6-phosphatase 
The activity of glucose-6-phosphatase was determined 
using a modified method of Nordlie and Arion (74). Micro-
somal suspension (1,3 mg protein/ml, final concentration) 
was incubated with glucose-6-phosphate (0,02 M, final 
concentration) in a volume of 1,5 ml in 0,02 M Tris-HCl, 
0 pH 7,4, for 20 min in a shaking water bath at 30 • The 
reaction was quenched by the addition of 1,0 ml 10% tri-
chloroacetic acid and the precipitated protein was spun 
down in a MSE 6L centrifuge at 2 000 rpm for 10 min. 
Reaction blanks were prepared by the addition of glucose-6-
phosphate to the incubation medium after precipitation of 
the protein. 1 ml of the supernatant was used to deter-
mine the inorganic phosphorus content as described by 
King (75). The absorbance was read at 660 nm on a 
Gilford spectrophotometer, and the inorganic phosphorus 
released/mg microsomal protein was determined by comparison 
with potassium dihydrogen phosphate standards. 
11.f 0-Demethylation of E-nitroanisole 
The 0-demethylation of E-nitroanisole was measured 
by a modification of the method of Netter et al. (76). 
A 2 mM solution of E-nitroanisole in 0,02 M Tris HCl, 
pH 7,4, was prepared by heating to 45°. The stock 
Solut ·o ~ n·tr · 1 k tat 37° for the durati·on in OL ~ i oaniso e was. ep 
of the assay. Microsomal suspension (0,6 mg protein/ml, 
final concentration) and E-nitroanisole (0,6 mM, final 
concentration) in 0,02 M Tris-HCl, pH 7,4 in a total 
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volume of 3,0 ml, were equilibrated to 37°. The reaction 
was initiated by the addition of NADPH generating system 
and initial reaction rates were recorded for about 5 min 
at 420 nm against a reference without NADPH generating 
system. 
11.g N-Demethylation of ethylmorphine 
The N-demethylation of ethylmorphine was measured 
according to the method of Stripp et al. (77). 1,5 ml 
microsomal suspension (0,6 and 2,0 mg protein/ml, final 
concentration, for phenobarbital and methylcholanthrene 
induced microsomes respectively) was equilibrated to 37° 
with NADPH generating system. The reaction was initiated 
by addition of 0,1 ml ethylmorphine (10 mM, final concen-
tration) and incubated for 10 min with shaking. The 
reaction was quenched by the addition of 0,5 ml 15% zinc 
sulfate and 5 min later, 0,5 ml saturated barium hydroxide 
was added. The precipitated protein was removed by 
centrifugation at 2 000 rpm, and 1,25 El of the supernatant 
was used for the determination of formaldehyde by the 
Hantzsch reaction of Nash (78). 0,5 ml Nash reagent was 
added to the supernatant and the colour allowed to develop 
at 60° for 30 min. The absorbance was read at 415 nm. 
A standard curve was constructed from solutions containing 
0,5 - 4,0 µg formaldehyde per ml. 
11.h Hydroxylation of benzpvrene 
The hydroxylation of benzpyrene was measured spectro-
photometrically by the method of Prough et al. (79) and 
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fluorimetrically by the me~hod of Nebert and Gelboin (80) 
as modified by Pelkonen et al. (81). In the spectre-
photometric method, 2,5 ml microsomal suspension containing 
80 µM benzpyrene was equilibrated to 30° in cuvettes. 
100 µl NADH (200 µM final concentration) was then added 
to both cuvettes and the reaction was immediately initiated 
\·.rith 50 pl NADPH (100 µM final concentration). The absorb-
ance changes at 454 nm, 401 nm and 428 nm were recorded 
with time, and initial rates were calculated for the 
change in absorbance at 401 nm and 428 nm relative to 
454 nm. In the fluorimetric method, 3,0 ml microsomal 
suspension was equilibrated with benzpyrene in acetone 
(80 µM - 320 µM, final concentrations) to 37°. The 
reaction was initiated with NADPH generating system and 
incubated for 15 min with shaking. The reaction was 
terminated with the addition of 0,1 ml cold acetone. The 
products were extracted from the incubation mixture by 
shaking with 3,25 ml !!_-heptane for 10 min. After cen-
trifugation at 2 000 rpm on a MSE 6L centrifuge for 10 min, 
1 ml of the organic layer was added to 5 ml lM NaOH, and 
extracted and centrifuged as before. Finally, the organic 
phase was removed, and the fluorescence of the aqueous 
phase was read on a Perkin Elmer 203 fluorimeter with 
excitation wavelength of 396 nm and emrnission wavelength 
of 522 nm. 
11.i Hydroxylation of biphenyl 
The 2- and 4-hydroxylation of biphenyl was measured 
fluorimetricdlly by the method of Creaven et al. (82) as 
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modified by Burke et al. (83). The incubation mixture 
(total volume 2,0 ml) contained microsomal suspension, 
NADPH generating system and biphenyl (2 µmol, final 
concentration), in 0,02 M Tris-HCl, pH 7,6. The micro-
somes and generating system were preincubated for 90 sec 
in teflon stoppered tubes in a shaking water bath. The 
react.ion was initiated with 0,5 ml biphenyl and oxygen 
was blown over the surface of the incubation mixture for 
20 sec. The incubation proceeded under oxygen for 5 min 
and the reaction was terminated with 0,5 ml SN HCl. The 
2- and 4-hydroxybiphenyl products were extracted from the 
reaction mixture by shaking with 7 ml n-heptane (containing 
1,5% iso-amyl alcohol to prevent emulsification) for 5 min 
at room temperature. After centrifugation for 10 min, 
2 ml of the heptane layer was added to 5 ml 0,1 M NaOH in 
a clean teflon stoppered tube and extracted and centrifuged 
as before. The heptane phase was removed and 2 ml of the 
aqueous phase pipetted into quartz fluorimeter cuvettes. 
0,5 ml 0:25 M succinic acid was added, and after mixing, 
the fluorescence was read with excitation and emission 
wavelengths of 275 nm and 330 nm respectively for the 
4-hydroxylated product, and 290 nm and 415 nm respectively 
for the sum of the 2- and 4-hydroxylated products. 
Reaction blanks containing biphenyl added to the inactiv-
ated microsomes and standards of 2- and 4-hydroxybiphenyl 
(in 96% ethanol) which were also added to the inactivated 
microsomes, were extracted in the same way. Standard 
curves of 4-hydroxybiphenyl over the range of 2,5 to 
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25 nmol/mg microsomal protein were prepared and the 
absorbance read at both sets of wavelengths. 2-hydroxy-
biphenyl (2,5 nmol/mg microsomal protein) and 4-hydroxy-
biphenyl (12,4 nmol/mg microsomal protein) standards were 
run daily. The concentration of the 2-hydrox-ybiphenyl 
products was determined as described by Creaven et al. (82). 
12. Lipid peroxidation 
Malonaldehyde formation, an index of lipid peroxidation, 
was measured as described by Ernster and Nordenbrand (84). 
The protein in the incubation sample was precipitated with 
trichloroacetic acid and the malonaldehyde production was 
measured colorimetrically with the thiobarbituric acid 
reaction. 
13. Reduced glutathione determination 
The reduced glutathione content of the sample used was 
estimated by the E-chloromercuribenzoate method of Stadtman 
( 85) . The increase in optical density due to 0,1 µmol 
reduced glutathione after 5 min incubation was 0,595 ± 0,005 
at 255 nm, indicating that the sample was 89-96% reduced. 
14. Sodium dodecyl sulfate gel electrophoresis 
Sodium dodecyl sulfate gel electrophoresis was run on 5,6% 
polyacrylamide gels containing 0,1% SDS using a modification 
of the method of Fairbanks et al. (86) and Welton and Aust 
( 8 7) • 10 cm glass electrophoresis tubes were thoroughly 
cleaned by soaking in warm SDS solution. The gels were 
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prepared by mixing the solutions in Table 1 in the follow-
ing proportions and order: 7 ml acrylamide, 5 ml lOx 
buffer, 2,5 ml SDS, 28 ml distilled water, 5 ml ammonium 
persulfate and 2,5 ml N,N,N' ,N'-tetramethylethylenediamine. 
The solution was mixed thoroughly and pipetted into the 
clean dry electrophoresis tubes. Each tube was carefully 
overlaid with a solution of 0,1% SDS, 0,15% ammonium 
persulfate and 0,05% N,N,N' ,N'-tetramethylethylenediamine 
using a pasteur pipette, to insure a uniform gel surface. 
The gels took about~ hr to polymerize. When polymeriza-
tion was complete, the surface of the gels was washed with 
electrophoresis buffer (Table 1) and the gel tubes were 
transferred to a Pleuger Acrylophor electrophoresis 
chamber containing the electrophoresis buffer. The gels 
were left to stand overnight at room temperature, and 
were pre-electrophoresed for about 2 hr at 5 V per cm 
using a LKB 3371E DC power supply before application of 
the sample. 
Microsomal samples for electrophoresis were prepared 
as follows: a mixture of 10 ml microsomal suspension 
(approximately 3,5 mg protein/ml) containing 10% sucrose, 
approximately 0,01% bromophenol blue (tracking dye), 1 rnM 
EDTA and 1% SDS was prepared. 5 or 10 µl of the micro-
somal suspension were then applied to the gel. Molecular 
weight markers bovine serum albumin, catalase, alcohol 
dehydrogenase and pepsin were prepared in the same way 
at a protein concentration of 0,5 mg/ml. Electrophoresis 
was performed in the dark at 4° with a voltage gradient 
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Table 1. Solutions for SDS gel electrophoresis 
Solution Ingredients 
Acrylamide 40 g acrylamide, 1,5 bisacrylamide/ 





lOx buffer pH 7,4 
Electrophoresis buffer 
0,4 M Tris, O,~ M sodium acetate, 
0,02 M EDTA, pH 7,4 
100 ml lOx buffer, 50 ml 2% SDS, 
850 ml water 
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of 5 V/cm which resulted in a current of 2 to 3 ma per 
tube, for approximately 8 hr. 
The gels were either stained for protein using Coomasie 
blue without shaking as described by Fairbanks et al. (86) 
or for cytochromes P-420 peroxidase activity using the 
benzidine-hydrogen peroxide stain of Clausen (88). The 
solutions used for the Coomasie blue staining procedure 
are given in Table 2. They were used in descending order 
for the times indicated. The benzidine-hydrogen peroxide 
stain was utilized after soaking the gels in 0,02 M Tris-
HCl containing 50% methanol to lower the SDS concentration. 
The gels stained with Coomasie blue were scanned at 550 nm 
using a Varian Techtron model 635 spectrophotometer with 
gel-scanning attachment and the cytochromes P-450 peaks 








Coomasie blue staining procedure for proteins 
after SDS gel electrophoresis 
blue Solvent Time for stainin9 
25% iso-propyl alcohol overnight 
10% acetic acid 
10% iso-propyl alcohol ca 8 hr 
10% acetic acid 
10% acetic acid overnight 




1. The effects of fluroxene treatment on the levels and 
activities of hepatic microsomal enzymes in induced animals 
Fluroxene treatment of phenobarbital and rnethylcholanthrene 
induced animals results in the degradation of cytochromes 
P-450, and the loss of cytochromes P-450 is accounted for 
by an equivalent loss of microsomal haem (Table 3). There 
appears to be no measurable loss of microsomal protein as 
measured by the microsomal marker enzyme, glucose-6-phos-
phatase (Table 3). The activities of this enzyme are 
identical in microsomes from induced rats with and without 
fluroxene treatment. There is also no decrease in the 
levels of microsomal NADPH-cytochrome c reductase or cyto-
chrome ~ 5 (Table 3). 
£-Nitroanisole 0-demethylase and biphenyl 4-hydroxylase 
activities and aniline binding are reactions which are 
catalysed non-specifically by type P-450 cytochromes 
(76, 89-91) and are decreased in proportion to the decrease 
in the levels of cytochromes P-450 follo~ing fluroxene 
injection (Tables 4, 5 and 6). 
It is confirmed that the activity of ethylmorphine 
N-demethylase is catalysed by cytochrome P-450 (26,32,92) 
because it is approximat~ly three times greater in pheno-
barbital induced microsomes, where cytochrome P-450 is 
induced, than in methylcholanthrene induced microsomes 
(Table 7). Ethylmorphine ~-demethylase activity is 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and methylcholanthrene induced animals (Table 7). 
The level of benzpyrene 3-hydroxylase activity is in-
creased following induction of cytochrome P-448 by methyl-
cholanthrene compared to phenobarbital induction of cyto-
chrome P-450 (Table 8), confirming that benzpyrene 3-hydroxy-
lation is catalysed by cytochrome P-448 (26,27,93,94,98). 
In phenobarbital induced rats, spectrophotometric measure-
ment of the formation of the 3-hydroxylated product showed 
that there was no decrease in the level of benzpyrene 
3-hydroxylase activity following fluroxene treatment (Table 
8). In methylcholanthrene induced rats, similar measure-
ments indicated that a large proportion of the benzpyrene 
3-hydroxylase activity was lost after fluroxene treatment 
(Table 8). The results of the spectrophotometric measure-
ment of the formation of the 9-hydroxylated product 
(A4 0lnm - A454 nm) of benzpyrene showed that fluroxene treat-
ment resulted in a decrease in activity in methylcholanthrene 
induced microsomes but no decrease in activity in pheno-
barbital induced microsomes. The decrease in the formation 
of 9-hydroxybenzpyrene (Table 9) was comparable to the 
decrease of the 3-hydroxylated product (Table 8). 
The results of fluorimetric measurements of benzpyrene 
hydroxylase activity are shown in Table 9. In pheno-
barbital induced microsomes, the results are identical 
using the spectrophotometric and fluorimetric methods. 
In methylcholanthrene induced microsomes, no decrease in 








































































































































































































































































































































































Table 9. The effect of fluroxene treatment on benzpyrene 
hydroxylase activity - a comparison between the spectro-
photometric and fluorimetric assay methods used 
Assay Method Induction CBenzpyreneJ % Relative to 
{µM) controls 
Spectrophotometric PB 80 103, 164a 
(A - ~ ) 401nm .n454nm 
4b MC 80 34 + -
Fluorometric PB 80 95 (72-125)c 
PB 160 159 (108-190)c 
PB 320 105 {90-128)c 
MC 80 99 + 4b -
MC 160 61 + lb -
MC 320 67 (68-66)c 
a Values for experiments done on two different preparations 
of microsomes. 
b Standard deviation for experiments on different prepara-
tions of microsomes. 
C 
Value, with range given in parenthesis, for experiments 
on one preparation of microsomes. 
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fluorimetric method using the same concentration of benz-
pyrene as in the spectrophotometric method (80 µM). How-
ever, as the concentration of benzpyrene is increased, a 
loss of activity is seen after fluroxene treatment, although 
not as great as the loss seen using the spectrophotometric 
method. The results obtained using the spectrophotometric 
method appear to be more reliable than those obtained 
using the fluorimetric method: in the fluorimetric method, 
with the long incubation time (15 min), initial reaction 
rates are not being measured; in addition, the products 
are extracted from the reaction medium in two stages and 
each step in the extraction procedure leads to a source 
of error. In contrast, in the spectrophotometric method, 
the formation of the products is determined by directly 
measuring initial reaction rates. 
The determination of biphenyl 2-hydroxylase activity, 
which is proposed to be specific for cytochrome P-448 
(89,93~ was found to be too inaccurate, and hence the 
results are not reported. 
The binding of ethyl isocyanide as a function of pH in 
phenobarbital and methylcholanthrene induced microsomes 
with and without fluroxene treatment is shown in Figures 
3 and 4 respectively. Following phenobarbital induction, 
the crossover pH is the same in animals treated or not 
with fluroxene (Table 10, figure 3). In rnicrosornes from 
rnethylcholanthrene induced, fluroxene treated animals, the 
crossover pH is considerably higher than that in the absence 
A




























































































































































































































































































































































































































































































































































































































































































































































of fluroxene treatment (Table 10, figure 4). 
Microsomes from rats induced with phenobarbital or 
methylcholanthrene and treated with fluroxene were green 
in colour in contrast to microsomes from animals not treated 
with fluroxene. The greenish colouration was similar to 
that found in microsomes from animals treated with AIA, 
which mediates, as does fluroxene, the destruction of cyto-
chromes P-450. In the case of AIA the colour has been 
attributed to green pigments which have been identified as 
oxyphlorins and porphyrins and are proposed to be degrada-
tion products of haem (95). The green colour resulting 
from fluroxene treatment was more apparent in microsomes 
from methylcholanthrene induced rats than phenobarbital 
induced rats and may also reflect the degradation of the 
haem moiety of cytochromes P-450. 
2. The effects of fluroxene on the levels of heoatic micro-
somal enzymes in vitro 
The carbon monoxide difference spectrum of reduced cyto-
chromes P-450 utilized in the measurement of cytochromes 
P-450 is shown in figure 5. The levels of cytochromes 
P-450 before and after incubation of the microsomal sus-
pension with fluroxene and NADPH generating system for 30 
min are shown for phenobarbital induced microsornes. The 
extent of degradation of cytochromes P-450 and haem in 
phenobarbital and rnethylcholanthrene induced microsomes 
in vitro is demonstrated in Table 11. Incubation of 







































FIGURE 5 The carbon monoxide difference spectrum of 
reduced cytochromes P- L.50 before (-) and 
ofter(---) . incubation of phenobarbital induced 
rnicrosomes with fluroxene and NADPH 






























































































































































































































































































































































































































































































































































or NADPH-cytochrome c reductase (Table 12). 
3a. Kinetics of the destruction of hepatic cytochromes P-450 by 
fluroxene in vitro 
The destruction of cytochromes P-450 by fluroxene in vitro 
followed first order kinetics. The decrease in the levels 
of cytochromes P-450 as a function of time in phenobarbital 
and methylcholanthrene induced microsomes is shown in 
figure 6. The first order rate plots for the destruction 
of cytochromes P-450 in phenobarbital and methylcholanthrene 
induced microsomes are linear as shown in figures 7 and 8. 
The first order rate constants for the degradation of cyto-
-2 
chromes P-450 by fluroxene were calculated to be 4,4 x 10 
min-l for phenobarbital and 4,9 x 10- 2 min-l for methylcholan-
threne induced microsomes. The total loss of cytochromes 
P-450 was 58% over 65 min in phenobarbital and 51% over 60 
min in methylcholanthrene induced microsomes. 
3b. K and V for the destruction of hepatic cytochromes P-450 
m max 
by fluroxene in vitro 
The K and V for the fluroxene mediated destruction of 
m max 
cytochromes P-450 in vitro were determined from Hanes plots 
(figures 9, 10 and 11) for various types of induction. 
The K values were found to vary with the different types 
m 
of induction, and V values were elevated in phenobarbital max 
and methylcholanthrene induced microsomes compared to 





























































































































































































































































































































































































































15 30 45 
Tl ME ( min) 
The destruction of cytochromes P- L.50 by 
fluroxene as a function of time in 
phenobarbital ( x) and methylchnl1Jnthrene O 
microsomes in vitro. Cytochromes P- l.50 














The first order rote plot for the destruction 
of cytochromes P-I.50 by fluroxene in 













The first order rote plot for the destruction 
of cytochromes · P - L.50 by fluroxene in 

























































































































































































































































































































































































































































































































































































Table 13. The effect of induction on the K and V x m ma 
values for the destruction of cytochromes P-450 by fluroxene 
in vitro 
Induction K V m max - --
(mM) (nmol cyts P-450/ 
mg mies protein/ 
7 min) 
None 1,76 + ,10 0,19 + ,02a - -
PB 0,87 + ,35 0,45 + , 21 - -
MC 3,32 + ,85 0,48 + ,16 - -
a nmol cyts P-450/mg mies protein/IO min 
4a. Interaction of metabolites of fluroxene with hepatic 
cytochromes P-450 in phenobarbital induced microsomes 
in vitro 
Four metabolites of fluroxene are trifluoroethanol, tri-
fluoroacetic acid, trifluoroacetaldehyde and bicarbonate 
(figure 1). Of these, only trifluoroethanol and trifluoro-
acetaldehyde bind to cytochromes P-450 giving a type I 
difference spectrum, whereas trifluoroacetic acid and 
bicarbonate do not interact with cytochromes P-450 in a 
spectrally observable manner in phenobarbital induced micro-
somes. The Ks value for trifluoroacetaldehyde binding to 
























































































































































































Trifluoroacetaldehyde appears to be negligibly metabolised, 
with an apparent V value of 0,9 + 0,4 nmol NADPH con-max 
sumed/mg microsomal protein/min being calculated at a 
concentration of 38 mN. Neither trifluoroacetic acid nor 
bicarbonate enhance carbon monoxide sensitive NADPH con-
sumption and, therefore, apparently do not undergo cyto-
chromes P-450 dependent metabolism. The K and K values s m 
for trifluoroethanol binding and metabolism are presented 
elsewhere (96). 
4b. The effects of metabolites of fluroxene on the levels of 
5. 
hepatic microsomal enzymes in vitro 
The lack of destruction of cytochromes P-450 in phenobarbital 
and methylcholanthrene induced rnicrosomes by metabolites of 
fluroxene is shown in Table 14. None of the metabolites 
appreciably degrade cytochromes P-450, and this is supported 
by the lack of destruction of microsomal haem by trifluoro-
acetaldehyde and bicarbonate in phenobarbital induced micro-
somes. None of the metabolites of fluroxene affect the 
levels of cytochrome £5 and NADPH-cytochrome c reductase in 
phenobarbital induced microsomes (Table 15). 
The effects of various compounds and experimental conditions 
on the fluroxene mediated degradation of hepatic cytochromes 
P-450 in vitro 
The effects of various compounds and different experimental 
conditions on the fluroxene mediated destruction of cyto-
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































induced microsomes, C0:02 {80:20; v/v) completely inhibited 
trefluroxene mediated destruction of cytochrornes P-450 as 
did totally anaerobic conditions. The extent of the des-
truction of cytochromes P-450 was not enhanced by saturating 
the microsornes with oxygen. Reduced glutathione did not 
inhibit the fluroxene mediated destruction of cytochromes 
P-450 in phenobarbital or rnethylcholanthrene induced micro-
somes. Cyanide did not inhibit the degradation of cyto-
chromes P-450 by fluroxene in phenobarbital induced micro-
somes. 
6. The effects of inhibitors on the fluroxene mediated degrada-
tion of hepatic cytochromes P-450 in vitro 
Total inhibition of the fluroxene mediated degradation of 
cytochromes P-450 was seen in the presence of 0,05 and 2,3 
mM metyrapone in phenobarbital and methylcholanthrene 
induced microsomes (Table 17). The destruction of cyto-
chromes P-450 by fluroxene was totally inhibited by high 
concentrations of SKF 525-A (330 µM) but low concentrations 
of this inhibitor (50 µM), did not diminish the fluroxene 
mediated degradation of cytochromes P-450 in phenobarbital 
or methylcholanthrene induced microsomes. 
7. Lipid Peroxidation 
Malonaldehyde production, under conditions of fluroxene 
mediated destruction of cytochromes P-450 in vitro in 
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As shown therein, the increase in malonaldehyde production 
caused by the addition of generating system was the same 
in the absence and presence of fluroxene. 
Table 18. Malonaldehyde production in phenobarbital 
induced microsomes in vitro 
Additions [Malonaldehyde] [Malonaldehyde J 
(mM) (nmol/mg mies protein) (nmol/mg mies 
protein/30 min) 
0 min 30 min 
- 0,14±-_0,10 0;40±0,07 0,26 
NADPH generating 0,02±-_0,0l 0,64±-_0,10 0,62 
system 
Fluroxene (30 mM) 0,83+0,18 0,93±-_0,32 0,10 
NADPH generating 1,56+0,70 2,13+0,40 0,57 
system+ fluroxene 
(30 mM) 
8a. The interaction of structural analogues of fluroxene with 
hepatic cytochromes P-450 in phenobarbital induced micro-
somes in vitro 
The structural analogues of fluroxene, e.~. ethyl vinyl 
ether, divinyl ether and 2,2,2-trifluoroethyl ethyl ether, 
all bind to cytochromes P-450 in a type I manner. The 
binding constants for these interactions were calculated 
to be 2,65 + 0,09 mM and 2,70 ± 0,85 mM for ethyl vinyl 
66 
ether and divinyl ether, respectively. Both of the vinyl 
ethers are metabolised by cytochromes P-450 as measured by 
NADPH consumption. K values of 3,33 + 0,04 mM and m 
1,25 + 0,21 mM and V values of 7,65 + 0,67 and 7,74 + max 
0,54 nmoles NADPH consumed/mg microsomal protein/min were 
calculated for ethyl vinyl ether and divinyl ether, res-
pectively. The Hanes plots were similar for both ethyl 
vinyl ether and divinyl ether and those for the binding 
and metabolism of ethyl vinyl ether are illustrated in 
Figures 13 and 14. Trifluoroethyl ethyl ether also binds 
to cytochromes P-450in a type I manner and is metabolised 
by cytochromes P-450. Details of the interaction of 
trifluoroethyl ethyl ether with cytochromes P-450 are 
reported elsewhere (48). 
Sb. Effects of analogues of fluroxene on hepatic microsomal 
enzymes in vitro 
In phenobarbital induced microsomes, neither trifluoro-
ethyl ethyl ether, ethyl vinyl ether nor divinyl ether 
destroy cytochromes P-450 (Table 19). However, in methyl-
cholanthrene induced microsomes, ethyl vinyl ether and 
divinyl ether degrade cytochromes P-450, whereas trifluoro-
ethyl ethyl ether does not (Table 20). Microsomal haem 
is also destroyed by ethyl vinyl ether and divinyl ether 
in methylcholanthrene induced microsomes and the loss of 
microsomal haem roughly parallels the loss of cytochromes 
P-450 (Table 20). In both cases, the% loss of haem/ 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































fluroxene (Table 11). Reduced glutathione does not inhibit 
the destruction of cytochromes P-450 by ethyl vinyl ether 
or divinyl ether in methylcholanthrene induced microsomes 
(Table 21) . 
Table 21. The effect of reduced glutathione on the des-
truction of cytochromes P-4~0 by ethyl vinyl ether and 
divinyl ether in methylcholanthrene induced microsomes 
in vitro 
Analogue GSH [cyts P-450] % Cyts P-450 
{rnM) ( 5rru'1) (nmol/mg mies 
lost --
protein) 
0 min 30 min 
- 2,08_±,04 2, 15.±., 05 0 
EVE (35) + 2,21::_,08 1,85±,04 16 
- 2,13:!:_,03 1,94:!:_,09 9 
DVE (22) + 2,27:!:_,01 l,5S_±,04 32 
-- 2,21±,06 1, 65:!:_, 0 5 25 
Neither ethyl vinyl ether nor divinyl ether affect the 
levels of cytochrome £5 and NADPH-cytochrome ~ reductase 
in methylcholanthrene induced rnicrosomes (Table 22). 
9. SDS gel electrophoresis of hepatic cytochrome P-450 
haemoproteins 



































































































































































































































































































































































in order to establish which type P-450 cytochromes are de-
graded by f1uroxene in vivo. 
Figures 15 and 16 show the scans of the cytochromes 
P-450 band patterns after SDS gel electrophoresis of pheno-
barbital and methylcholanthrene induced microsomes. Norm-
ally only four protein bands corresponding to the haem 
proteins located by the peroxidase stain could be detected, 
but when good separation was achieved, a fifth band was 
detected between bands 3 and 4. This band appeared to 
merge with band 3 when separation was not optimal. Pheno-
barbital and methylcholanthrene induction gave rise to 
different cytochromes P-450 protein band patterns. The 
band patterns for phenobarbital induced microsomes were 
similar to those reported by Welton and Aust (87). In 
rnethylcholanthrene induced microsomes, the protein bands 
differed considerably from those reported by Welton and 
Aust (87) but were similar to those reported by Welton 
et al. (28). Fluroxene treatment of induced animals did 
not alter the protein band patterns relative to animals 
receiving the corresponding inducing agent only. This 
observation was confirmed by integration of the cytochromes 
P-450 peaks: the loss of cytochromes P-450 as measured by 
integration is negligible and within experimental error 
(Table 23). 
To test the validity of the results obtained using SDS 
electrophoresis, this technique was utilized to quantitate 
the cytochromes P-450 bands from phenobarbital induced 
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FIGURE 15 Scans of the cytochromes P-450 protein bands after separation 
by SOS gel electrophoresis of phenobarbital plus fluroxene (A) 
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FIGURE 16 Scans of the cytochromes P-450 protein bands after 
separation by SOS gel electrophoresis of methylcholan-


































































































































































































































































































































































































































































































































































phenobarbital induced animals. AIA has been proposed to 
specifically destroy the haem moiety of cytochrome P-450 
(51). The scans of the cytochrornes P-450 protein bands 
of hepatic microsomes isolated from animals treated or 
not treated with AIA are identical although considerable 
degradation of cytochromes P-450 is observed by spectral 
assay (Table 23). In addition, no loss of cytochromes 
P-450 is measurable by integration (Table 23). 
These results are inconsistent with the proposed 
s11ecificity of 1\IA to degrade cytochrome P-450 in vivo 
and with the degradation of cytochromes P-450 by fluroxene 
demonstrated in this thesis (see DISCUSSION). The dis-
crepancy in the results possibly arises because the SDS 
gel electrophoresis is performed at high detergent concen-
tration which results in the disruption of the environment 
of the haem causing the denaturation of cytochromes P-450. 
During SDS gel electrophoresis of isolated, purified cyto-
chromes P-450, haem is shown to be liberated from the 
cytochrome P-450 haemoproteins, and appears as a fore-
running band of free haem. In addition, a single haem 
plus protein band is detected (99). It appears, therefore, 
that the areas corresponding to the different type P-450 
cytochrornes reflect the sum of the concentrations of the 
haernoprotein plus apoprotein. Since SDS gel electro-
phoresis of rnicrosomes from animals treated with fluroxene 
or AIA show no changes in the relative amounts of the 
cytochromes P-450 present compared to animals not treated 
(Table 23), it appears that fluroxene and AIA degrade 
78 
cytochromes P-450 by destroying the haem moiety of the 
protein, without affecting the apoprotein. Furthermore, 
it appears that this technique cannot be utilized to quan-
titate cytochromes P-450 where the haem but not the protein 




Fluroxene has been shown to be toxic to many animal 
species and to man (4-11). Since the toxicity of 
fluroxene appears to arise from the metabolic conversion 
of fluroxene by the mixed function oxidases to toxic 
intermediates or metabolites, we have investigated the 
metabolism of fluroxene by hepatic microsomal mixed 
function oxidases in vivo and in vitro. Aspects of the 
metabolism of fluroxene and the fluroxene mediated degrada-
tion of cytochromes P-450, will be discussed herein. 
The effects of fluroxene on the levels and activities 
of cytochromes P-450 and proteins associated with the cyto-
chromes P-450 drug metabolising pathway have been investi-
gated (INTRODUCTION, equation 2). Of these enzymes, 
fluroxene appears to degrade only cytochromes P-450 and 
does not affect the levels of cytochrome b 5 or NADPH-
cytochrome ~ reductase in vivo or in vitro (Tables 3, 11 
and 12) . In addition, there appears to be no loss of 
total microsomal protein as measured by the microsomal 
marker enzyme, glucose--6-phosphatase (Table 3) ( 10 l) . 
Fluroxene degrades cytochromes P-450 by chemically 
modifying only the h,3em moiety of the haemoprotein in vivo. 
This is evident because the loss of microsomal haem is 
equivalent to the loss of cytochrornes P-450 in vivo 
(Table 3), whereas the apoprotein is not degraded, as 
measured by SDS gel electrophoresis (Table 23). Fluroxene 
also appears to only degrade the haem moiety of cytochromes 
80 
P-450 in vitro; the loss of haem is equivalent to the loss 
of cytochromes P-450 in phenobarbital induced microsomes, 
although not in methylcholanthrene induced microsomes 
(Table 11). In addition, there is no appearance of cyto-
chromes P-420 (figure 5), the denatured form of cytochromes 
P-450 which results from the binding to microsomal proteins 
of the free haem moiety released following denaturation 
of cytochromes P-450 (102). The presence of cytochromes 
P-420 would have been expected if the conformation of the 
enzyme was altered but the haem moiety not destroyed. 
In order to establish whether the degradation of cyto-
chromes P-450 is accompanied by a loss of activity of 
these haemoproteins in vivo and to establish which type 
P-450 cytochromes are degraded by fluroxene, a series of 
cytochrornes P-450 dependent reactions were measured after 
fluroxene treatment of animals. Some of the cytochromes 
P-450 dependent reactiorsutilized are known to be catalysed 
non-specifically by type P-450 cytochromes, ~-~· E-nitro-
anisole 0-dernethylation and biphenyl 4-hydroxylation (76, 
89) . In addition, the binding of aniline to cytochrornes 
P-450 appears to be non-specific (90,91). In contrast, 
other cytochrornes P-450 dependent reactions utilized have 
been shown to be catalysed by particular type P-450 cyto-
chromes. For example the hydroxylation of benzpyrene is 
catalysed specifically by cytochrome P-448 (26,27,93,94,98), 
whereas the N-demethylation of ethylrnorphine appears to be 
catalysed by cytochrome P-450 but definitely not by cytochrome 
* P-448 (26,32,92). Furthermore, the binding of ethyl 
* The specificity of ethylmorphine N-demethylase activity in 
this thesis refers to cytochromes P-450 in male rats. 
81 
isocyanide to ferrocytochromes P-450 differs with cyto-
chrome P-450 and cytochrome P-448 and can be utilized to 
distinguish these forms of the haemoproteins (25,26). 
Since, following fluroxene treatment, the losses of 
E-nitroanisole 0-dernethylase and biphenyl 4-hydroxylase 
activities and aniline binding are equivalent to the loss 
of cytochromes P-450 (Tables 4, 5 and 6), it would appear 
that the decrease in concentration of cytochromes P-450, 
as measured by spectral assay, reflects a decrease in 
enzymatic activity of this group of enzymes. The reactions 
which are specifically catalysed by different type P-450 
cytochromes were used to distinguish which type P-450 cyto-
chromes are preferentially degraded by fluroxene in pheno-
barbital and methylcholanthrene induced microsomes. Since, 
following fluroxene treatment of phenobarbital induced 
animals, ethylmorphine N-demethylase activity is decreased 
(Table 7), but benzpyrene hydroxylase activity is not 
(Tables 8 and 9), it would appear that cytochrome P-450 is 
degraded by fluroxene, and cytochrome P-448 is not. In 
methylcholanthrene induced animals the loss of both 
ethylmorphine N-demethylase and benzpyrene hydroxylase 
activities (Tables 7 and 8) indicate that both cytochrome 
P-450 and cytochrome P-448 are degraded by fluroxene in 
vivo following this type of induction. In order to try 
and establish which of these type P-450 cytochromes is 
preferentially degraded by fluroxene in methylcholanthrene 
induced microsomes, values have been assigned for the levels 
of cytochrome P-450 and cytochrome P-448 in this type of 
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preparation of microsomes determined on the basis of a 
large body of scientific literature (26,28,89,93,103). 
In methylcholanthrene induced microsomes, where the 
total cytochromes P-450 content is 1,6 nmol/mg microsomal 
protein, approximately 1 nmol/mg microsomal protein appears 
to be cytochrome P-448 which catalyses the hydroxylation of 
benzpyrene, and the remaining 0,6 nmol/mg microsomal protein 
constitutes the other type P-450 cytochromes. There is a 
65% loss of benzpyrene hydroxylase activity following the 
degradation of cytochromes P-450 by fluroxene in vivo in 
methylcholanthrene induced microsomes (Table 8) and thus, 
of the 1 nmol/mg microsomal protein cytochrome P-448, 0 1 65 
nmol/mg microsomal protein is degraded. Of the 0,6 nmol/mg 
microsomal protein type P-450 cytochromes remaining, 0.2 nrnol/mg 
microsomal protein is degraded by fluroxene (Table 7). 
Thus, of the 0,8 nmol/mg microsomal protein cytochromes P-450 
degraded by fluroxene in methylcholanthrene induced animals, 
0,65 nmol/mg microsomal protein is cytochrome P-448 and 
0,2 nmol/rng microsomal protein the other type P-450 cyto-
chromes. Although the exact amounts of the different type 
P-450 cytochromes in microsomes following methylcholanthrene 
induction are unknown, it appears that cytochrome P-448 is 
preferentially degraded by fluroxene in vivo following 
methylcholanthrene induction. Further support for these 
proposals was obtained from the changes in the crossover 
pH following the degradation of cytochromes P-450 in vivo. 
The ethyl isocyanide crossover pH of purified preparations 
of cytochrome P-450 and cytochrome P-448 are 7,85 and 6,85 
83 
respectively (25,26). In methylcholanthrene induced 
animals, the change in crossover pH from 6,9 to 7,5 following 
fluroxene treatment (figure 4, Table 10) indicates that 
cytochrome P-448 is preferentially degraded by fluroxene 
in vivo. Following fluroxene treatment of phenobarbital 
induced animals, the crossover pH remains the same as that 
found for microsomes from phenobarbital induced (figure 3, 
Table 10) and uninduced animals (69), indicating that either 
cytochrome P-450, which is induced by phenobarbital, or the 
type P-450 cytochrome predominating in uninduced microsomes, 
is degraded by fluroxene. However, the lack of degrada-
tion of cytochromes P-450 following fluroxene anaesthesia 
of uninduced rats (104) suggests that fluroxene degrades 
cytochrome P-450 in preference to the type P-450 cytochrome 
predominating in uninduced microsomes. 
The degradation of cytochrome P-450 in phenobarbital 
induced microsomes and cytochrome P-448 in methylcholan-
threne induced microsornes has also been demonstrated in 
vitro. From studies of the kinetics of the degradation 
of cytochrornes P-450 by fluroxene, it was found that the 
total losses of cytochromes P-450 were equivalent for 
phenobarbital and methylcholanthrene induced microsomes 
indicating that both cytochrome P-450 and cytochrome P-448 
are degraded by fluroxene. In contrast, AIA has been 
proposed to specifically degrade cytochrome P-450 (51). 
Support for this proposal arises from studies of the 
kinetics of the degradation of cytochromes P-450 by AIA 
in vitro (105). The extent of loss of cytochromes P-450 
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following degradation by AIA differs considerably for 
phenobarbital and methylcholanthrene induced rnicrosomes: 
in phenobarbital induced rnicrosomes, 50% of the cytochromes 
P-450 was lost over 65 min, whereas in methylcholanthrene 
induced microsomes, only 16% was lost over the same period 
of time indicating that only cytochrome P-450 is degraded 
by AIA in both phenobarbital and methylcholanthrene induced 
microsomes. 
Although fluroxene degrades both cytochrome P-450 and 
cytochrome P-448, this anaesthetic agent does not appear 
to affect the levels of any other type P-450 cytochromes 
in hepatic microsomes i~ vitro. In uninduced microsomes, 
where neither cytochrome P-450 nor cytochrome P-448 are 
thought to predominate (25,87,106), attempts to determine 
the first order rate constant for the degradation of cyto-
chromes P-450 by fluroxene in vitro were not successful 
because the decrease in the levels of cytochromes P-450 
was very slight. In addition, the V value for the max 
degradation of cytochromes P-450 by fluroxene in uninduced 
microsomes was considerably lower than that observed for 
phenobarbital and methylcholanthrene induced microsomes 
(Table 13). The decreased ability of fluroxene to 
degrade cytochromes P-450 in uninduced microsomes may 
result from the initial low levels of cytochromes P-450, 
but more likely reflects the ability of fluroxene to 
degrade cytochrome P-450 and cytochrome P-448, but not the 
other type P-450 cytochromes. 
Since fluroxene appears to degrade cytochrome P-450 in 
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phenobarbital induced microsomes and both cytochrome P-450 
and cytochrome P-448 in methylcholanthrene induced microsomes, 
K values for the degradation of cytochromes P-450 by flurox-m 
ene were measured in order to establish whether different 
mechanisms exist for the fluroxene mediated degradation of 
cytochromes P-450 in the differently induced microsomes. The 
K values for the degradation of cytochromes P-450 by flurox-m 
ene are shown to differ for the variously induced microsomes 
(Table 13). The K value for the degradation of cytochromes m 
P-450 by fluroxene in phenobarbital induced microsomes is 
identical to K for the binding of fluroxene to cytochrome s 
P-450 and the K for the cytochrome P-450 dependent conversion m 
of fluroxene to trifluoroethanol (48,96). Therefore, in 
phenobarbital induced microsomes, it appears that the binding 
of fluroxene to cytochrome P-450 is rapid and prior to the 
rate limiting step in the degradation of cytochromes P-450 
by fluroxene. In phenobarbital induced microsomes, only 
cytochrome P-450 is involved in the metabolism of fluroxene, 
and only cytochrome P-450 appears to be degraded by fluroxene. 
The K value for the degradation of cytochromes P-450 m 
by fluroxene in methylcholanthrene induced microsomes is 
higher than that in phenobarbital induced microsomes and 
differs from the K for the conversion of fluroxene to m 
trifluoroethanol in methylcholanthrene induced microsomes 
( 9 6) • The difference between the K values for the m 
metabolism of fluroxene by cytochrome P-450 and the fluroxene 
mediated degradation of cytochromes P-450 in methylcholan-
threne induced microsomes probably reflectsthe involvement 
of different type P-450 cytochromes in the metabolism of 
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fluroxene and in the fluroxene mediated degradation of 
cytochrornes P-450 with this type of microsornes. It has, 
in fact, been demonstrated in methylcholanthrene induced 
microsomes that cytochrome P-450 is the main type P-450 
cytochrome catalysing the conversion of fluroxene to 
trifluoroethanol (48), whereas cytochrome P-450 and cyto-
chrome P-448 are both degraded by fluroxene. 
Metabolic activation of fluroxene appears to be a pre-
requisite for the degradation of cytochromes P-450 by 
fluroxene. The degradation of cytochromes P-450 requires 
NADPH and oxygen (Tables 11 and 16), both of which are 
cofactors for cytochromes P-450 dependent reactions as well 
as for other microsomal reactions such as haem oxygenase 
and stearate desaturase (107-109). Carbon monoxide, an 
inhibitor of cytochromes P-450 dependent reactions (110), 
fully inhibits the degradation of cytochromes P-450 by 
fluroxene (Table 16), whereas cyanide (0,1 mM), an inhibitor 
of the other microsomal reactions mentioned (111,112), has 
no effect on the fluroxene mediated degradation of cytochromes 
P-450 (Table 16). Other inhibitors of the cytochromes P-450 
dependent drug metabolising pathway, metyrapone and SKF 
525-A (113-116), also inhibit the fluroxene mediated degra-
dation of cytochromes P-450 (Table 17), although inhibition 
by these compounds is ~ore complex and will be discussed 
later (DISCUSSION, pages 89,92). · Thus the cytochromes 
P-450 dependent drug metabolising pathway is definitely 
involved in the degradation of cytochromes P-450 by 
fluroxene as well as the metabolism of fluroxene (48,96). 
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Since metabolic activation of fluroxene appears to be 
essential for the fluroxene mediated degradation of cyto-
chromes P-450, the possible sequence of events during 
the metabolism of fluroxene which results in the degrada-
tion of cytochromes P-450 is as follows: fluroxene binds 
to ferricytochrome P-450 to form the fluroxene-ferricyto-
chrome P-450 complex which accepts one electron from NADPH 
to form the fluroxene-ferrocytochrome P-450 complex. The 
rate limiting step in the cytochromes P-450 drug metabolising 
pathway has been shown to be subsequent to the binding of 
molecular oxygen to the ferrocytochromes P-450-substrate 
complex (117). Therefore, since oxygen does not enhance 
the fluroxene mediated destruction of cytochromes P-450 
(Table 16), the rate limiting step in the degradation of 
cytochromes P-450 by fluroxene occurs after the fluroxene-
ferrocytochrome P-450 oxygenated complex has accepted the 
second electron from NADPH. The degradation of cytochromes 
P-450 takes place at either of the subsequent two steps in 
the metabolism of fluroxene as illustrated in figure 17. 
Since metabolic activation of fluroxene is essential 
for the fluroxene mediated degradation of cytochromes P-450, 
it is possible that the metabolism of fluroxene results in 
a reactive metabolite which catalyses the degradation of 
cytochromes P-450. However, none of the known or proposed 
stable metabolites of fluroxene can mimic the degradation 
of cytochromes P-450 by fluroxene (Table 14), although some 
bind to and are metabolised by cytochromes P-450. Of all 

























































































































































































































































































glucuronide of trifluoroethanol is biologically inactive 
and as a result was not studied. Hence, it is possible 
that metabolic activation of fluroxene by cytochromes 
P-450 may give rise to a transient reactive intermediate 
which is responsible for the degradation of cytochromes 
P-450. Since cytochrome P-450 is primarily responsible 
for the metabolism of fluroxene to trifluoroethanol, it 
is possible that this enzyme also catalyses the formation 
of the proposed reactive intermediate which then can degrade 
cytochrome P-450 and cytochrome P-448. Alternatively, 
cytochrome P-450 may catalyse the metabolism of fluroxene 
to trifluoroethanol, but cytochrome P-450 and/or cyto-
chrome P-448 may catalyse the formation of the reactive 
intermediate from fluroxene which can then react with cyto-
chrome P-450 or cytochrome P-448. By using inhibitors 
of specific cytochromes P-450 dependent reactions, it was 
possible to distinguish between these alternatives. 
The inhibitors of cytochromes P-450 dependent reactions 
were selected because of their proposed specificity for 
different type P-450 cytochromes. Metyrapone has been 
proposed to bind specifically to cytochrome P-450 (118) and 
to specifically inhibit cytochrome P-450 dependent reac-
tions (119). There was total inhibition of the fluroxene 
mediated degradation of cytochromes P-450 in phenobarbital 
induced microsomes in the presence of low (50 µM) and high 
(2,3 mM) concentrations of metyrapone (Table 17); since 
cytochrome P-450 is the main type P-450 cytochrome de-
graded by fluroxene in phenobarbital induced microsomes 
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and fluroxene is primarily metabolised by cytochrome P-450, 
inhibition of the fluroxene mediated degradation of cyto-
chromes P-450 by metyrapone in phenobarbital induced 
microsomes was anticipated. 
In rnethylcholanthrene induced microsomes,where fluroxene 
degrades both cytochrome P-450 and cytochrome P-448,there 
is also total inhibition of the fluroxene mediated degrada-
tion of cytochromes P-450 by metyrapone (Table 17). Since 
metyrapone reportedly inhibits cytochrome P-450 dependent 
reactions specifically and since fluroxene is metabolised 
primarily by cytochrome P-450, the total inhibition of the 
fluroxene mediated degradation of cytochrornes P-450 by 
metyrapone probably indicates that metyrapone inhibits 
the fluroxene mediated degradation of cytochromes P-450 by 
inhibiting the formation of the reactive intermediate by 
cytochrome P-450. Therefore, it appears that two type 
P-450 cytochrome molecules are involved in the degradation 
of cytochromes P-450 by fluroxene: cytochrome P-450 alone 
is involved in the formation of the reactive metabolite 
which can then degrade cytochrome P-450 or cytochrome P-448. 
Inhibition of the formation of the reactive metabolite by 
cytochrome P-450 results in total inhibition of the fluroxene 
mediated degradation of cytochromes P-450 in phenobarbital 
and methylcholanthrene induced microsomes. However, the 
partial inhibition of the conversion of fluroxene to tri-
fluoroethanol in phenobarbital induced microsomes remains 
unexplained. Perhaps, for some reason, the metabolism of 
fluroxene to trifluoroethanol is not as susceptible to 
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inhibition as the fluroxene mediated degradation of cyto-
chromes P-450. It is interesting to note that carbon 
monoxide also totally inhibits the fluroxene mediated 
degradation of cytochromes P-450 but not the metabolism 
of fluroxene to trifluoroethanol (Table 16) and the same 
explanation may hold for both of these inhibitors of 
cytochromesP-450 dependent reactions. 
In methylcholanthrene induced microsomes, where two 
type P-450 cytochrome molecules are involved in the degrada-
tion of cytochromes P-450 by fluroxene, the kinetics of 
degradation are pseudo first order with respect to cyto-
chromes P-450. Oxygen, fluroxene and NADPH are the other 
components of the degradation reaction on whose concentra-
tions the first order kinetics could depend, but these 
compounds are all present in excess. Therefore, because 
two different type P-450 cytochromes appear to be involved 
in the degradation of cytochromes P-450 by fluroxene in 
methylcholanthrene induced microsomes, the pseudo first 
order kinetics observed suggest that only one type P-450 
cytochrome is involved in the rate limiting step of the 
reaction. From the similarity between the rate of 
degradation of cytochromes P-450 by fluroxene in phenobarb-
ital induced microsomes where only cytochrome P-450 is 
degraded, and methylcholanthrene induced microsomes, where 
cytochrome P-450 and cytochrome P-448 are degraded, it 
appears that the type P-450 cytochrome involved in the 
rate limiting step i.s the same for both types of induction. 
Since only cytochrome P-450 appears to be involved in the 
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formation of the reactive metabolite in both types of 
induction, this could be the rate limiting step of the 
reaction. 
The inhibition of the fluroxene mediated degradation 
of cytochromes P-450 by SKF 525-A was also studied. 
SKF 525-A has been proposed to specifically bind to a type 
P-450 cytochrome other than that induced by phenobarbital. 
This type P-450 cytochrome may be cytochrome P-448 or any 
of the other type P-450 cytochromes (118). Since fluroxene 
appears to bind to cytochrome P-450 and SKF 525-A is pro-
posed to bind to any type P-450 cytochrome, except cyto-
chrome P-450, no inhibition of the binding of fluroxene to 
cytochrome P-450 was anticipated. However, although 
SKF 525-A does not inhibit the binding of fluroxene to 
cytochrome P-450 at concentrations below 100 µM, it inhibits 
the binding of fluroxene to cytochromes P-450 at concen-
trations of 100 µM to 330 µM (97). The type of inhibition 
observed was of a non-competitive or mixed type in contrast 
to the competitive inhibition usually observed with SKF 525-A 
where it competes for binding to the type I binding site of 
cytochrornes P-450 (113,120). Therefore, the specificity 
of SKF 525-A for binding to a type P-450 cytochrome other 
than cytochrome P-450 appears to occur only at concentra-
tions below 100 µM. 
Since low concentrations of SKF 525-A (50 µM) do not 
inhibit the fluroxene mediated degradation of cytochromes 
P-450 in phenobarbital or methylcholanthrene induced micro-
sornes (Table 17),SKF 525-A is probably specific for a type 
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P-450 cytochrome other than cytochrome P-450 or cytochrome 
P-448. The role played by the type P-450 cytochrome for 
which SKF 525-A is specific in the fluroxene mediated 
degradation of cytochromes P-450, appears to be minor 
since inhibition of this type P-450 cytochrome does not 
measurably affect the degradation of cytochromes P-450 by 
fluroxene; this result confirms the proposal that fluroxene 
does not affect the levels of type P-450 cytochromes other 
* than cytochrome P·-450 and cytochrome P-448 . The inhibi-
tion of the fluroxene mediated degradation of cytochromes 
P-450 seen at higher concentrations of SKF 525-A (330 µM) 
in phenobarbital induced microsomes, supports the proposal 
that SKF 525-A non-specifically inhibits type P-450 cyto-
chromes at this concentration (Table 17 J • Therefore, the 
inhibition studies done at 330 µM SKF 525-A confirm that 
cytochromes P-450 are involved in the degradation of cyto-
chromes P-450 by fluroxene, but do not assist in the 
determination of the role played by the different type P-450 
cytochromes. 
In an attempt to establish the nature of the reactive 
intermediate in the fluroxene mediated degradation of 
cytochromes P-450, the ability of various analogues of 
fluroxene to degrade cytochromes P-450 was investigated. 
As a result of these studies, it is established that the 
reactive intermediate arises from the vinyl moiety of the 
* Alternatively, perhaps the site of inhibition of cytochromes 
P-450 by SKF 525-A is not the same as the site of degrada-
tion of this enzyme by fluroxene, but this seems unlikely 
as SKF 525-A binds to the haem moiety of cytochromes P-450 
(113,115,118,120) which is also the site of degradation of 
the haemoprotein by fluroxene. 
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molecule. The saturated analogue of fluroxene, trifluoro-
ethyl ethyl ether, does not contain a vinyl moiety and is 
unable to degrade cytochromes P-450 in phenobarbital or 
methylcholanthrene induced microsomes in vitro (Tables 19 
and 20) and in vivo (104). However, the analogues of 
fluroxene which contain the vinyl moiety, ethyl vinyl ether 
and divinyl ether, both degrade cytochromes P-450 in methyl-
cholanthrene induced microsomes although they do not degrade 
cytochromes P-450 from phenobarbital induced microsomes 
(Tables 20 and 19). As with fluroxene, metabolic activa-
tion of ethyl vinyl ether and divinyl ether appears to be a 
prerequisite for the degradation of cytochromes P-450 since 
no destruction of cytochromes P-450 is observed in the 
absence of the electron donor NADPH (Table 20). The extent 
of degradation of cytochromes P-450 is greater with divinyl 
ether which contains the two vinyl moieties than with ethyl 
vinyl ether which contains a single vinyl moiety. 
Should ethyl vinyl ether and divinyl ether degrade 
cytochromes P-450 by the same mechanism as fluroxene, it 
would appear that the difference between the types of cyto-
chromes P-450 degraded by these ethers lies in the difference 
between the reactive intermediates formed from fluroxene 
and from ethyl vinyl ether or divinyl ether. With ethyl 
vinyl ether and divinyl ether, the lack of degradation of 
cytochromes P-450 in phenobarbital induced microsomes could 
be explained if cytochrome P-448 only is responsible for 
catalysing the formation of the reactive intermediates from 
these ethers. Alternatively, cytochrome P-450 could 
catalyse the formation of the reactive intermediate which 
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then specifically degrades cytochrome P-448 but not cyto-
chrome P-450. 
Lipid peroxidation is one mechanism whereby the degrada-
tion of cytochromes P-450 is known to occur (50,121,122). 
Lipid peroxidation can occur in the presence of microsomes 
and NADPH in vitro (123). For this reason, the fluroxene 
mediated degradation of cytochromes P-450 in vitro was 
measured in the presence of EDTA, a potent inhibitor of 
lipid peroxidation (123,124). Furthermore, the production 
of malonaldehyde, a measure of the extent of lipid peroxida-
tion, was not enhanced in incubation mixtures in which 
degradation of cytochromes P-450 had occurred to a consider-
able extent (Table 18). These results confirm that lipid 
peroxidation is not involved in the degradation of cytochromes 
P-450 and the reactive intermediate which appears to be in-
volved in the fluroxene mediated degradation of cytochromes 
P-450 does not arise from or result in the peroxidation of 
lipids. 
Since the degradation of cytochromes P-450 involves the 
vinyl moiety of the ethers, a likely form of the reactive 
intermediate would be that of an epoxide. Epoxides are 
highly strained molecules and as a result are extremely 
reactive. Epoxides appear to be formed during the metab-
olism of allyl containing barbiturates, pesticides and 
polycyclic hydrocarbons by cytochromes P-450 (19,20,125). 
The degradation of cytochromes P-450 by AIA has been pro-
posed to involve the formation of an epoxide across the 
double bond of the allyl moiety of the molecule (49). 
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Fluroxene, ethyl vinyl ether and divinyl ether each contain 
a vinyl moiety which could be oxidised to an epoxide. 
Although reduced glutathione which is a strong nucleo-
phile capable of deactivating epoxides (125) or glutathione 
S-transferase, a cytoplasmic enzyme, alone do not inhibit 
the fluroxene mediated degradation of cytochromes P-450, 
the combination of glutathione S-transferase and reduced 
glutathione partially inhibit the fluroxene mediated degrada-
tion of cytochromes P-450 (126). This combination has 
been shown to react with strong electrophiles, such as 
epoxides (127-129). Therefore, it appears that the reac-
tive intermediate produced from fluroxene may take the form 
of an epoxide. Studies in progress with the microsomal 
enzyme epoxide hydrase are expected to confirm whether an 
epoxide is involved in the fluroxene mediated degradation 
of cytochromes P-450. 
The implications of the results of this investigation 
into the degradation of cytochromes P-450 by fluroxene 
appear to be two-fold. One important aspect of this inves-
tigation is the elucidation of the degradation of cytochromes 
P-450 as a possible mechanism for drug-drug interactions. 
Fluroxene is amongst the first medically used compounds 
shown to degrade cytochrornes P-450 in vivo and in vitro and 
the degradation of cytochromes P-450 should be considered, 
along with induction, inhibition of and competition with 
the components of the drug metabolising pathway in explaining 
the complexities of drug-drug interactions in drug therapy 
when more than one drug is prescribed. Studies have been 
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recently completed in our laboratory to establish in which 
functional groups the ability to specifically degrade cyto-
chromes P-450 resides; these include the allyl, alkyne, 
nitro, nitrile, and some halogenated moieties (130). Com-
pounds such as AIA and the allyl containing barbiturates 
contain the allyl functional group and have been shown to 
degrade cytochromes P-450. It is hoped that the knowledge 
obtained from establishing which functional groups have 
the ability to degrade cytochromes P-450 can be extrapolated 
to mec:.ically used compounds and thus the use of drugs which 
degrade cytochromes P-450 can be avoided or at least cogni-
zance taken of their ability to alter the metabolism of 
themselves and other xenobiotics. This should especially 
be noted in the case of anaesthetic agents where not only 
the patient is affected but also medical personnel involved 
in administration of the anaesthetic. 
Secondly, the possibility was revealed that fluroxene, 
in its ability to degrade the haem moiety of cytochromes 
P-450, may produce experimental porphyria. AIA, a compound 
known to produce porphyria, degrades the haem moiety of 
cytochromes P-450 in vivo to green pigments, which have 
been proposed to be oxyphlorins and unidentified porphyrins 
(95). Furthermore, it has been postulated that the ability 
of AIA to induce experimental porphyria may be related to 
its ability to degrade cytochrome P-450 in vivo (56,58,131). 
Fluroxene is also capable of degrading the haem moiety of 
cytochromes P-450 and a similar green colouration was ob-
served after the fluroxene mediated destruction of cytochromes 
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P-450 in vivo. Although the mechanism of fluroxene des-
truction of cytochromes P-450 may be different to the 
destruction of cytochrome P-450 by AIA, the similarities 
in the ability of both agents to specifically destroy 
cytochromes P-450 by haem degradation to green products, 
has led us to believe that fluroxene may be a chemical 
inducer of porphyria. This is currently under investiga-
tion in our laboratory and preliminary studies have shown 
that fluroxene treatment of animals elevates the levels of 
porphyrins and precursors relative to controls and there-
fore probably does induce experimental porphyria. 
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